SecBot SecBot
PRESS-RELEASE ·Filed May 29, 2026

MNKD

MannKind
BULLISH
Impact 8/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This FDA approval for a pediatric indication transforms the commercial opportunity for Afrezza. Monitor next quarterly revenue and prescription trends for pediatric uptake.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.77
T+0 close · May 29, 2026 · via day close
Latest settled
+7.96%
T+60 · $4.07
Vs SPY
+6.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 29 $3.77entry
  2. T+1 · 6mo ago −6.37%α −6.64% · $3.53
  3. T+5 · 6mo ago −10.88%α −10.58% · $3.36
  4. T+20 · 5mo ago +12.47%α +14.26% · $4.24
  5. T+60 · 3mo ago +7.96%α +6.77% · $4.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MannKind received FDA approval for Afrezza® in children and adolescents aged 6+. This expands the addressable patient population for the company's inhaled insulin product, a significant label expansion for a single-product biotech with a $1.1B market cap. The stock has a history of high volatility on news events.

Key Facts

  • FDA approved Afrezza for use in children and adolescents aged 6+ with diabetes
  • This is a label expansion for MannKind's sole marketed product, Afrezza
  • Company has a $1.1B market cap, early-stage biotech dynamics apply

Financial Impact

Afrezza is MannKind's only commercial product; approval in pediatric population (ages 6+) expands TAM meaningfully. No revenue or market size figures provided in press release.

future revenueaddressable market

Risk Factors

  • Pediatric adoption of inhaled insulin may be slow due to safety perception or switching costs
  • Single-product concentration risk remains, Afrezza still competes with injectable insulins and GLP-1 agonists
  • No financial guidance or revenue contribution projections provided in this release

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303773

Track record

17 reports on MNKD

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  3. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
  4. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
  5. Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
  6. Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
  7. Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
  8. Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
  9. Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
  10. May 29, 202624w ago Press Release Bullish 8/10 Viewing Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 29, 2026